Future studies, namely those including more recent standards of care such as anti-CD38 monoclonal antibodies, will determine the extent to which the CD27−:CD27+ T cell ratio is a useful maker of tumor specificity and response to lenalidomide-based combinations in MM. Here, CD27 is linked to neoplasm.